Loading
A phase 1/2 trial of Sacituzumab tirumotecan in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) is a phase 1/2 interventional study registered as NCT06637423 by Merck Sharp & Dohme LLC, with 32 participants planned, started 2024-12-20 and due to reach its primary completion in 2029-03-14. Interventions recorded: Sacituzumab tirumotecan, Rescue medication and Supportive care measures.
Shares Non-muscle-invasive bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.